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Chromatinherpesvirus (KSHV) is the etiologic agent of Kaposi's sarcoma. K-Rta and K-bZIP
are two major viral transcription factors that control reactivation of this virus. Here we report a genome-wide
analysis of transcriptional capacity by evaluation of a comprehensive library of 83 putative KSHV promoters.
In reporter assays, 34 viral promoters were activated by K-Rta, whereas K-bZIP activated 21 promoters. When
K-Rta and K-bZIP were combined, 3 K-Rta responsive promoters were repressed by K-bZIP. The occupancy of
K-Rta and K-bZIP across KSHV promoters was analyzed by chromatin immunoprecipitation with a viral
promoter-chip in BCBL-1 cells. In addition, acetylation of local histones was examined to determine
accessibility of promoters during latency and reactivation. Finally, 10 promoters were selected to study the
dynamics of transcription factor recruitment. This study provides a comprehensive overview of the
responsiveness of KSHV promoters to K-Rta and K-bZIP, and describes key chromatin changes during viral
reactivation.
© 2009 Elsevier Inc. All rights reserved.Introduction
Kaposi's sarcoma-associated herpesvirus (KSHV) is the most
recently discovered member of the human gamma-herpesviruses
(Ganem, 2006). Like other members of this viral subfamily, KSHV
establishes latency in B cellswith a capacity to reactivate in response to
certain stimuli, including phorbol esters such as 12-O-tetradecanoyl-
phorbol-13-acetate (TPA). This reactivation of lytic replication leads to
an ordered sequence of gene expression and viral DNA replication,
enabling the assembly and release of infectious virus particles (Sun
et al.,1999). One KSHV gene in particular, a strong transactivator called
K-Rta/ORF50, has the capacity to initiate the entire reactivation
cascade when expressed in cells harboring latent virus (Gradoville et
al., 2000; Lukac et al., 1998; Sun et al., 1998). This critical role for K-Rtaed at UC Davis Cancer Center,
o, CA 95817, USA. Fax: +1 916
645 2nd Avenue, Sacramento,
), hkung@ucdavis.edu
ll rights reserved.in the life cycle of the virus has produced a large body of work aimed at
elucidating its effects on various viral promoters, cellular binding
partners, regulation of transcription, and putative DNA binding motifs
(Carroll et al., 2007; Chang et al., 2005; Chen et al., 2000; Song et al.,
2003;Wang et al., 2001). To date, much of this work has depended on
reporter assays and DNA binding experiments, in which the proteins
and selected promoter targets are examined in transient expression
assays using cell lines such as 293, BJAB, SLK, and others. Although,
the results have been highly informative regarding the molecular
mechanisms of K-Rta action, these studies were often carried out in
the absence of other viral proteins which could modify the action of
K-Rta. K-bZIP, a positional homologue of BZLF1 in Epstein–Barr virus
(Gruffat et al., 1999; Lin et al., 1999), has been implicated in a broad
array of viral processes, including regulation of transcription, cell
cycle, host antiviral response, and DNA replication (AuCoin et al.,
2004; Izumiya et al., 2003a, 2003b, 2005, 2007; Rossetto et al., 2007;
Wang et al., 2004; Wu et al., 2001). K-bZIP serves as a coregulator of
K-Rta (Izumiya et al., 2003a). However, the extent of co-recruitment
and the potential regulatory effects of K-bZIP and K-Rta have yet to be
investigated in the context of KSHV reactivation from latency.
The stable association of latent viral episomes with host cell nuclei
is critical for viral persistence, and this association is presumed to
involve epigenetic control of chromatin. One of the levels of such
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histone proteins or the “histone code” (Strahl and Allis, 2000). Among
thesemodiﬁcations, acetylation of histone 3 on lysine 9 (H3acK9), and
the methylation at lysine 4 (H3meK4), are strongly associated with
“open” chromatin, undergoing active transcription (Berger, 2007).
H3acK9 modiﬁcation-speciﬁc antibodies are particularly valuable in
the study of the active chromatin state. One of the well-established
chemical triggers of gamma-herpesvirus reactivation is sodium
butyrate treatment, which is believed to act through an inhibition of
the histone deacetylase complex (HDAC). Different doses of sodium
butyrate potentiate varying kinetic patterns of viral gene expression in
BCBL-1 cells (Yu et al., 1999). In addition, sodium butyrate treatment
synergizes with exogenous expression of K-Rta to drive reactivation in
a cell line model based on recombinant KSHV (rKSHV.219), (Vieira
and O'Hearn, 2004). Early studies on the latent origins of DNA
replication of both EBV and KSHV have also shown local patterns of
increased histone 3 acetylation (Day et al., 2007; Stedman et al., 2004),
aswell as demethylation of the K-Rta promoter, a step linked to histone
acetylation, associated with an increase in spontaneous reactivation
(Chen et al., 2001). Additionally, the transient expression of CBP
(CREB-binding protein), a histone acetyl-transferase (HAT), leads to K-
Rta transactivation in a HAT-dependent manner (Lu et al., 2003).
In this work, we performed a screen of all the putative promoters
of the KSHV genome, with the intent to deﬁne the respective roles of
K-Rta and K-bZIP during the reactivation cascade. For promoters
strongly activated by K-Rta, the effects of cotransfection with K-bZIP
were also tested. To study recruitment of these two viral proteins, the
same promoter regions were subsequently printed on glass slides to
serve as a substrate for hybridization analysis by ChIP-on-chip assay
(Ren et al., 2000). This latter assay served as a tool to examine
recruitment of both factors across all the putative promoters of the
KSHV genome in primary effusion lymphoma (PEL) cells undergoing
reactivation from latency. In addition, the association of viral
promoters with acetylated histone 3 at lysine 9 (H3acK9), as a
marker for open chromatin, was examined. Finally, a set of ten viral
promoters were selected for an analysis of temporal regulation of
recruitment and chromatin remodeling of the KSHV episome during
reactivation.
Results
K-Rta responsive promoters
K-Rta is a master switch protein of KSHV reactivation, and has
been shown to activate many KSHV promoters such as PAN, K9,
K12, K14, ORF57, K-bZIP, vIL-6, vMIP-1α, and ORF8 (Chang et al.,
2002; Chen et al., 2000; Deng et al., 2002; Duan et al., 2001; Liao et
al., 2003; Zhang et al., 1998; Ziegelbauer et al., 2006). The potency
of K-Rta transactivation varies widely across different promoters
and experimental conditions, from ﬁve-fold to over a thousand-
fold. Accordingly, we developed an approach to simultaneously
evaluate all promoters in the same setting, to reveal which viral
promoters represent the most potent potential targets of K-Rta. The
strategy was based on the understanding that the open reading
frames of herpesvirus genes contain little intervening non-coding
DNA, such that promoter regions are generally found immediately
upstream of each ORF. Although the promoter segments in our
library would miss any transcriptional control elements located
within the coding region itself, this approach is an effective way to
deﬁne the potential for transactivation by individual viral genes and
provides the basal information to investigate the more complex
control of transcription in the physiologically relevant context.
Open reading frames that were known to have alternative or distant
transcriptional start sites at the time of the library design were
included, such as the LTc and LTi promoters of LANA (Matsumura et
al., 2005; Staudt and Dittmer, 2006). The predominant pattern ofnonstandard transcription for KSHV appears to be common
polyadenylation site usage among neighboring genes, in which
the functional mRNA for each open reading frame still initiates from
a directly upstream promoter (Zheng, 2003). Thus, this library of
putative promoters represents a powerful tool to reveal basal
regulatory interactions for the majority of the genes of KSHV. These
experiments were conducted in 293 cells because of their
consistently high transfection efﬁciency. This line is also permissive
for KSHV infection and reactivation, thus presenting a valid cellular
context for the study of viral replication.
To survey K-Rta responsive promoters, the reporter constructs
were each cotransfected with a K-Rta expression plasmid. Protein
expression was conﬁrmed by immunoblotting (Fig. 1, right upper
panel). A 10-fold threshold was chosen for signiﬁcance to eliminate
experimental background. By this criterion, K-Rta activated 34 of 83
promoters tested (Fig. 1). Under a more stringent 30-fold cutoff, 19 of
the 83 promoters showed strong activation by K-Rta. These genes
mainly encode transactivator/regulators (K-bZIP and ORF57),
immune-evasion/cellular homologs (ORF4, K2, ORF70/K3, K6, K9,
K12, K14, K15 and ORF75), DNA replication-related proteins (ORF6,
ORF9, K-bZIP, ORF59, and Ori-RNA), proteins related to nucleotide
synthesis/repair (ORF21 and ORF61), and several structural proteins
(ORF8, ORF22, ORF19, ORF43, ORF47, ORF64 and ORF67). Among the
most highly activated promoters, the well established targets K-bZIP,
ORF57, ORF59, and PAN all displayed greater than 200-fold activation.
Additionally, twelve putative late promoters, whose gene expression
was previously shown to be signiﬁcantly inhibited by Cidofovir (Lu et
al., 2004), were also responsive to K-Rta. These late genes are ORF19,
ORF21, ORF22, ORF23, ORF28, ORF42, K10, ORF61, ORF64, ORF67, K12,
and ORF75. The majority of these predicted late gene targets were
activated less than 30-fold (7 of 12, 58%), whereas three (ORF21,
ORF22, ORF28) were activated between 30 and 40-fold. By contrast,
the ORF61 and K12 promoters were activated 76 and 99-fold,
respectively. This screen served to identify a number of novel potential
targets for K-Rta activation, especially among late genes, and agrees
well with previous work on early gene targets.
K-bZIP responsive promoters
Using transient expression assays, we examined responsiveness of
all KSHVputative promoters to K-bZIP in 293 cells, and found that 21 of
the 83 KSHV promoters displayed at least some activation by K-bZIP,
using a 10-fold cutoff (Fig. 1). The highest activation was observed for
the ORF23 promoter at 21-fold over vector control. K-bZIP alone did
not activate the promoters of any of the eight established DNA
replication related genes (ORF6, ORF9, ORF40-41, ORF44, K-Rta, K-bZIP,
ORF56, and ORF59) nor immediate-early genes (K-bZIP and ORF57).
Interestingly, K-bZIP appeared to transactivate promoters of viral
structural genes such as tegument proteins (ORF19 and ORF63),
glycoproteins gH and gL (ORF22 and ORF47) and capsid proteins
(ORF11, ORF25, and ORF65). These results suggest a model inwhich K-
bZIP has transcriptional activation functions in later time points of
gene expression. Indeed, 10 of the promoters activated by K-bZIP were
among those determined to be Cidofovir-sensitive (Lu et al., 2004).
The potential of K-bZIP to act as a modest transactivator across a broad
range of KSHVpromoters is a novelﬁnding,whichmay be important in
considering its larger role in viral reactivation.
Combinatorial effects of K-bZIP and K-Rta on major targets of K-Rta
transactivation
Building on these results, transcriptional effects of K-Rta andK-bZIP
in combination were examined in cotransfection assays. Experiments
were performed for all 34 of the K-Rta target promoters showing 10-
fold or greater levels of response; each promoter reporter plasmidwas
cotransfected with K-Rta alone, or both K-Rta and K-bZIP. Protein
Fig. 1. Transactivation by K-Rta (light), or K-bZIP (dark). 293 cells were cotransfected with KSHV promoter reporter constructs along with K-Rta, K-bZIP, or a vector control. Fold
activation over vector transfected lysates are shown for each promoter. Upper right panel shows conﬁrmation of expression by immunoblotting.
Fig. 2. Functional interaction between K-Rta and K-bZIP on K-Rta responsive promoters.
(A) Conﬁrmation of expression levels for both factors. (B) Effects of K-bZIP expression on
K-Rta transactivation. Luciferase value of K-Rta alone was normalized as 1 (solid line),
the broken line at 2-fold represents a doubling of K-Rta activity attributable to K-bZIP
cotransfection. Values below1-fold represent K-bZIP repression of K-Rta transactivation.
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bodies (Fig. 2A). Consistent with previous work, early lytic promoter
activation mediated by K-Rta (ORF57 and K-bZIP promoters) was
signiﬁcantly reduced by K-bZIP co-expression (Izumiya et al., 2003a;
Liao et al., 2003), as was the activation of the K15 promoter (Fig. 2B).
Surprisingly, the majority of the other K-Rta responsive promoters
(23 of 31, 74%) were instead enhanced by K-bZIP, displaying two or
greater-fold increase in reporter activity over K-Rta alone. The
greatest extent of enhancement was observed for the K9 and ORF67
promoters, at 6.9 and 9.1-fold over K-Rta alone, respectively. A strong
majority of the Cidofovir-sensitive late targets of K-Rta (10 of 12,
83%) were among those displaying signiﬁcant transcriptional
cooperativity with K-bZIP, and even the ORF42 and K12 promoters
showed a potentially signiﬁcant increase, although it did not pass
our 2-fold criterion for deﬁning synergy. Interestingly, the capacity of
K-bZIP for enhancement of transcriptional activation of K-Rta is not
well predicted by its own direct action on promoters; less than a
quarter (5 of 23, 22%) of the synergistically activated promoters
made the 10-fold threshold for K-bZIP activation in the single-factor
screening. The only other promoter which could be signiﬁcantly
activated individually by both K-bZIP and K-Rta, ORF47, still showed
positive transcriptional cooperativity, but fell short of the 2-fold mark.
The broad diversity of K-Rta target promoters enhanced by K-bZIP
raises the possibility that the mode of action may be indirect, rather
than through individual sequence-speciﬁc protein–DNA interactions
between K-bZIP and each of the synergized promoters. Reciprocally,
the promoters responsive to K-bZIP alone, but not to K-Rta, do not
show signiﬁcant synergistic effect by K-Rta (data not shown); this
ﬁnding suggests that the two factors do not act on the samemotifs and
that their direct protein–protein interactions alone are insufﬁcient to
direct transcriptional synergy.
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chromatin immunoprecipitation
As demonstrated by the reporter assay screen, K-Rta has many
transactivation targets in the viral genome. In order to examine which
of these potential targets of K-Rta are actually occupied during
reactivation, we designed a custom viral promoter array chip based
on the same putative promoter fragments examined by reporter assay.
Although not a comprehensive map of the entire viral genome, this
array enabled analysis of transcription factor recruitment to the
putative and established promoters for every known KSHV gene
simultaneously. In brief, ﬁxed chromatin complexes from latent or
reactivating KSHV-positive primary effusion lymphoma cells were
immunoprecipitated with a puriﬁed polyclonal antibody to K-Rta or
IgG as a speciﬁcity control.We employed thewell-characterizedK-Rta-
inducible TREx BCBL1-Rta cells (Nakamura et al., 2003) for these
experiments in order to ensure a robust and speciﬁc reactivation from
latency. The initial focuswas on a delayed-early time point of 12 h after
induction. In order to minimize overexpression of K-Rta, the cell
culturemediumwas changed after 4 h to remove residual doxycycline.
This pulse induction was conﬁrmed to be sufﬁcient to produce strong
expression of the late-class glycoprotein, K8.1 by 24 h post induction
(Fig. 4). Enriched IP-DNAwas subjected to linear ampliﬁcation, labeled,
and hybridized to the customviral promoter chip against labeled input
DNA. The Cy3–Cy5 ratios for each spot on the viral promoter array
served as an indication of the relative enrichment of that promoter
fragment by the antibody, and therefore as a measure of target protein
occupancy on the promoter at the time of ﬁxation (Fig. 3B).
Of the 22 promoters that were more than 3-fold enriched in the
K-Rta immunoprecipitate for the 12 h time-point, most (14 of 22,
64%) were also signiﬁcant potential targets for K-Rta transcriptional
activation in 293 cells by the reporter assay screen in Fig.1. However, of
the 7 most highly enriched promoters (N5-fold enrichment) for K-Rta
association; vIL-6 (K2), Ori-RNA, vMIP-1a (K6), K-bZIP, Kaposin (K12),
ORF59, and ORF75, only two (K-bZIP and ORF59) were among the 6
major transactivation targets of K-Rta (>100-fold in 293 cells), despite
the fact that we expect all of these major targets to be transcribed at
this time point in this system (Nakamura et al., 2003). The relative
scarcity of K-Rta on promoters with known binding motifs despite
ample protein expression (Fig. 4) suggests that another level of
regulation is involved in the context of reactivating latent genomes,
that may limit the accessibility of some potential targets of K-Rta
binding and transactivation. In contrast, no viral promoter was more
than 2-fold enriched by the K-Rta ChIP assay without reactivation (Fig.
3A). Similarly, an IgG control ChIP did not show any enrichment in the
same 12-hour induced PEL cells (2-fold cutoff, Fig. 3C).
In order to address speciﬁc disagreements between transactivation
potential of K-Rta in 293 cells and recruitment of K-Rta in BCBL-1,
several additional reporter assays were performed in the same K-Rta
inducible BCBL-1 cell line used for the ChIP experiments. Five
promoters that displayed K-Rta recruitment in infected cells (N3.5-
fold), yet failed to respond to K-Rta in 293 cells, were examined in
this context alongside seven known K-Rta transcription targets as
positive controls. Reporter plasmids were transfected into TREx-K-Rta
BCBL-1. At 36 h post-transfection, K-Rta expression was induced with
doxycycline, and luciferase activity was measured 12 h after K-Rta
induction. This time-point was chosen to correlate directly with the
K-Rta recruitment experiment (Fig. 3A). The majority of the
promoters of interest (4 of 5) displayed enhanced reporter activity
in BCBL-1 as compared to 293 cells, with 3 promoters (ORF37p,
ORF45p, ORF46p) achieving the 10-fold cutoff in these cells (Fig. 5A).
This ﬁnding suggests that either B-cell speciﬁc transcriptional factor(s)
or viral factor(s) are required for effective transactivation of these
promoters. The expression level of K-Rta under these conditions is
shown in Fig. 5B. In particular, the ORF37 promoter was activated over
50-fold, for which we detected less than 10-fold activation by K-Rta in293 cells. Similarly, the promoters of K6, K12, and theOri-RNAwere also
notably enhanced in BCBL-1. The only putative promoter which
appeared to be an occupancy site of K-Rta during reactivation, without
appreciable K-Rta transactivation by reporter assay, was ORF2, which
displayedno signiﬁcant reporter activity in either context. Interestingly,
all seven examined promoters that were activatedmore than 10-fold in
293 cells were again activated in BCBL-1 at least 10-fold; this ﬁnding
supports our initial approach.
Genome-wide promoter array analysis of K-bZIP recruitment by
chromatin immunoprecipitation
When the ChIP-on-chip assay was performed on induced TREx
BCBL1-Rta cells using the puriﬁed antibody raised against K-bZIP, the
binding proﬁle was more restricted than the one observed for K-Rta.
Strikingly, all three repression target promoters (K15, ORF57, and
K-bZIP) were more than 6-fold enriched for K-bZIP occupancy
(Fig. 3D). The K-bZIP promoter was the most strongly enriched
target, at more than 9.5-fold over input hybridization levels.
Additionally, we also measured greater than 6-fold enrichment of
the ORF4 and ORF75 promoters, although neither of these showed
signiﬁcant (2 or greater fold) potential for transcriptional synergy or
repression between K-bZIP and K-Rta in the reporter assay screen.
Using a less stringent (4-fold) cutoff, K-bZIP was found to be
associated with six additional promoters at 12 h post reactivation:
K1, ORF6, ORF8, K6, ORF45, and K8.1. Interestingly, none of the
eleven K-bZIP ChIP association targets were signiﬁcant (greater than
10-fold) direct transactivation targets of K-bZIP by the reporter assay
screen. Indeed, among this set, the highest transactivation attribu-
table to K-bZIP alone was the ORF45 promoter, at 10-fold over vector
alone. This ﬁnding raises the hypothesis that the coactivation
potential of K-bZIP is not mediated through direct binding.
KSHV promoter association with acetylated histones during latency
and reactivation
To further investigate the state of the viral chromatin in PEL cells
during reactivation, a ChIP assay was performed using an antibody
against acetylated lysine at position 9 of histone 3, which is a well-
established marker of “open” or active promoters. Acetylated histone
associationwas proﬁled for 12-hour doxycycline treated cells (Fig. 6B),
as well as for latent cells not treated with doxycycline (Fig. 6A). In
reactivation, the most highly enriched promoters for H3acK9 (N12-
fold) at the12-hour timepointwere somewhat unexpected:K2 (vIL-6),
ORF2 (DHFR), MIR2 (K5), ORF16 (vBCL-2), ORF47 (gL), and K-bZIP. Of
these six most highly associated promoters, only K2 and K-bZIP
promoters were associatedwith (N5-fold) K-Rta occupancy at this time
point. Examination of the H3acK9-associated promoters at a less
stringent 5-fold cutoff revealed a total of 48 enriched promoters, more
than half of the entire complement of KSHV. These included the great
majority of the K-Rta-associated promoters (18 of 21, 86%, N3-fold), as
well as all the promoters on which K-bZIP was detected (11 of 11, N4-
fold). Interestingly, this analysis also identiﬁed two clusters of late gene
promoters that were depleted for the acetylated histone mark; the
region fromORF19–ORF33, as well as ORF61–ORF65. These areas agree
well with regions of Cidofovir-sensitive late genes, and as such may
represent regions of the genome tightly regulated by chromatin
structure during reactivation.
Strikingly, when the state of viral chromatin was examined in
latently infected cells, only two array promoter fragments were
enriched for H3acK9 association more than six-fold over input DNA
(Fig. 6A). The strongest enrichment (7.5-fold) was on the ORF73-Lc
(LANA) constitutive latent promoter, followed by the fragment
corresponding to the KSHV terminal repeat sequence (6.2-fold),
which serves as the latent origin of replication. Of the 11 array spots
that displayed a greater than 4-fold increase, nine (82%) were
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Fig. 4. Immunoblotting for K-Rta and K-bZIP expression during reactivation of TREx
BCBL1-Rta cells following dox treatment. Expression levels of K-Rta, K-bZIP, and K8.1 are
shown for all time points considered in this study. K-Rta expression is detectable by 4 h
after treatment, while both K-Rta and K-bZIP are expressed strongly by 12 h. GAPdH
served as a loading control.
81T.J. Ellison et al. / Virology 387 (2009) 76–88promoters enriched more than 5-fold in the H3acK9 ChIP assay after
doxycycline induction. This ﬁnding is suggestive of a low but
detectable background level of spontaneous reactivation in the TREx
BCBL1-Rta cells under these conditions.
Studies of dynamics of K-Rta and K-bZIP recruitment
To verify the observations made with the ChIP-on-chip method, 10
promoters were selected for individual analysis, using real-time
quantitative PCR. This set focused on the previously characterized
targets of K-Rta binding (K2, K6, PAN, K-bZIP, ORF57, K12). For those
promoters that have published K-Rta response elements (RRE), real-
time PCR primer pairs were designed to directly target those regions
(Table 2). The greater sensitivity of the PCR-based method also
enabled analysis of a dilution of the immunoprecipitated DNA directly,
without additional PCR-based linear ampliﬁcation. TREx BCBL1-Rta
cells were ﬁxed at 4, 12, and 24 h after doxycycline treatment, and
ChIP was performed with speciﬁc antibodies to study the recruitment
of both viral transcription factors, as well as to examine association
with acetylated H3K9. Comparison of the qPCR samples harvested at
12 h with those analyzed by ChIP-on-chip revealed agreement
between these two methods for all 10 promoters assayed (Fig. 7).
The vIL6 (K2), vMIP-1a (K6), PAN, and Kaposin (K12) promoters were
themajor sites of K-Rta occupancy at 12 h by both assays, although the
fold enrichment was much greater in the qPCR assay (25–120-fold) as
compared to the ChIP-on-chip assay (3–12-fold, Fig. 3B). The
difference may be due to the sensitivity of the detection methodolo-
gies, or the comparative enrichment over input DNA (ChIP-on-chip)
versus the comparison of fold enrichment over an IgG ChIP control
(qPCR method). Likewise, K-bZIP binding across the validation set
agreed well, with ORF57 and K-bZIP promoters displaying the highest
levels of recruitment, and negligible occupancy on promoters absent
from the ChIP-on-chip hybridization (PAN, K12) (Figs. 7B and C).
The ﬂexibility of the real-time qPCR approach enabled further
investigation of the temporal regulation of K-bZIP and K-Rta
recruitment. The primer set included 5 promoters on which K-bZIP
showed greater than 2-fold transcriptional synergy of K-Rta activity
(ORF9, K2, K6, ORF21, ORF64), as well as two K-bZIP-repressed
promoters (K-bZIP, ORF57), and 3 promoters on which K-bZIP did not
affect K-Rta activation (PAN, ORF59, K12). All 10 promoters selected
for more detailed analysis displayed potential for activation by K-RtaFig. 3. Genomewide promoter association proﬁles for K-Rta and K-bZIP in TREx BCBL1-Rta ce
input DNA are shown with standard deviations determined by paired replicate spots. (A
distribution at 12 h after inductionwith dox. (C) Control IgG ChIP-on-chip for 12-hour induce
genomic position; all fragments which were enriched greater than 5-fold are labeled for clagreater than 10-fold (Fig. 1), and 5 of them were among the most
potent K-Rta transactivation targets by reporter assay, at greater than
90-fold activation in 293 cells. These time-course analyses in the PEL
cells revealed that K-Rta was recruited to an increasingly larger set of
its potential transactivation targets as the reactivation progressed over
time. At 4 h after induction, only 5 of the examined K-Rta target
promoters displayed recruitment of greater than 5-fold over the IgG
control. These included strong early promoter targets PAN and K12, as
well as less potent transactivation targets ORF9, K2, and K6. By 12 h, 7
of 10 were observed at this stringency, whereas 9 of the 10 showed
K-Rta recruitment by 24 h (Fig. 7). The additional recruitment at later
time points included promoters of early and delayed-early genes such
as ORF59 and K-bZIP, and at 24 h, the late gene promoter of ORF21.
Another late gene promoter, ORF64, did not exceed 4.5-fold K-Rta
enrichment by 24 h. Altogether, these results demonstrate that K-Rta
distribution across the selected set of target promoters is regulated
temporally during the progression of KSHV reactivation from latency.
The genome-wide ChIP-on-chip results for H3acK9 demonstrated
a correlation between the increase in promoters associated with open
chromatin and the progression of reactivation. Delayed and late gene
promoters such as ORF59, ORF64 and ORF21 showed comparatively
less enrichment from an H3acK9 pull-down (less than 50-fold),
especially at 4 and 12 h time points, although all three increased
appreciably by 24 h (Figs. 7A, C). In contrast, very early target
promoters PAN, K-bZIP, and K6 exhibited greater than 100-fold
enrichment for H3acK9 as early as 4 h, and increased thereafter to
200 or greater fold by 12 h. For all ten promoters examined, signiﬁcant
levels of H3acK9 associationwere observed before or concurrent with
K-Rta or K-bZIP binding. The ORF9 promoter, which could be activated
14-fold by K-Rta in reporter assays, was strongly and consistently
associated with H3acK9 (N200-fold), but did not exceed a 6-fold
enrichment for K-Rta recruitment during the 24-hour time course
analyzed. In contrast, the potent K-Rta target promoter, ORF57, was
only 5 to 15-fold enriched for K-bZIP and K-Rta binding while in the
context of comparatively low (14–45-fold over IgG) association with
H3acK9 (Fig. 7B). This result indicates that viral chromatin structure
may determine the accessibility of potential transactivation targets
over time.
As a next step, a potential correlation between mode of activation
and recruitment of K-bZIP was examined. The ten promoters selected
for more detailed analysis included ﬁve which appeared to be
synergistically activated by K-bZIP when tested in combination with
K-Rta. Of those, four (K2, K6, ORF9, and ORF64, 80%), displayed
detectable K-bZIP occupancy (8–17-fold) during the 4 and/or 12 h
time points, with a loss of association by 24 h post reactivation (Fig.
7A). Additionally, each of these promoters displayed a stable or
increasing association with acetylated histone 3 at lysine 9, across the
12 and 24 h time points. The additional late gene synergy target, the
ORF21 promoter, only displayed K-Rta occupancy at 24 h, indicating
that synergistic activation observed in reporter assays was likely due
to indirect effects. K-Rta was most heavily recruited to the K2 and K6
early synergy promoters at 4 and 12 h (35–128-fold over IgG),
tapering off by 24 h. Among three promoters on which K-bZIP had no
effect (positive or negative) on K-Rta transactivation in 293 cells, none
appeared to be signiﬁcantly bound by K-bZIP in the reactivating PEL
cells (all less than 5-fold over IgG; PAN, ORF59, K12), showing
speciﬁcity of this experiment (Fig. 7C). On the other hand, two viral
promoters on which K-bZIP produces a repressive effect on K-Rta
transactivation, ORF57 and K-bZIP, were the most heavily enriched
sites for K-bZIP occupancy within the set of 10 promoters assayed by
real-time qPCR-ChIP (Fig. 7B). The peak recruitment of K-bZIP to itslls. Normalized background-subtracted Cy3–Cy5 ratios of linear-ampliﬁed IP-DNA over
) K-Rta promoter occupancy in latent cells with no doxycycline addition. (B) K-Rta
d cells. (D) K-bZIP association at 12 h after inductionwith dox. Promoters are ordered by
rity.
Fig. 5. Transactivation of selected promoters in TREx BCBL1-Rta cells. Promoter reporter
constructs were transfected into TRExBCBL1-Rta cells which were subsequently
induced to express K-Rta and initiate reactivation by dox treatment for 12 h. (A) Fold
induction of relative luciferase units between untreated (no K-Rta) and dox-treated
cells. (B) Expression level of K-Rta by western blot in uninduced or induced TREx
BCBL1-Rta cells at 12 h. GAPdH is included as a loading control.
82 T.J. Ellison et al. / Virology 387 (2009) 76–88own promoter was at 24 h (111-fold over IgG), whereas the ORF57
promoter had a peak at 12 h after induction. Interestingly, the
comparative levels of K-bZIP occupancy at these two promoters across
the 4, 12, and 24 h time points paralleled the recruitment of K-Rta in a
manner suggestive of co-recruitment in a regulatory complex.
Discussion
This work establishes an overview of K-bZIP and K-Rta inter-
actions with the entire complement of putative promoters contained
within the KSHV genome. Although some capacity for K-bZIP-
mediated transactivation has been previously shown with GAL4
fusions of N-terminal deletions of K-bZIP via Ini1/hSNF5 (Hwang
et al., 2003), as well as a potential for recruitment of CREB-binding
protein (Hwang et al., 2001), this is the ﬁrst time that full-length K-
bZIP has been demonstrated to activate viral promoters. The experi-
mental investigation of the combined effects of K-bZIP and K-Rta
together revealed an unexpected and signiﬁcant capacity for tran-
scriptional cooperativity between these two viral gene products. This
ﬁnding was in marked contrast to our earlier ﬁndings, based on a
detailed study of the K-bZIP, ORF57, and PAN promoters, in which the
former two were repressed by K-bZIP expression, and the latter
unaffected (Izumiya et al., 2003a). Synergy between ZEBRA and Rta of
EBV in reactivation from latency is well established (Carey et al., 1992).
Additionally, in our analyses K15 was identiﬁed as an additional viral
promoter target for K-bZIP-mediated repression. K15 is a complex
spliced transmembrane protein, which may play an important role in
modulation of host cell gene expression during reactivation (Brink-
mann et al., 2007; Choi et al., 2000). Although the speciﬁc role of K15 in
reactivation has not yet been established, microarray analysis of the
TREx BCBL1-Rta cells by others places this gene in the same expression
class as K-bZIP and ORF57, on the basis of the timing by which theFig. 6. Genomewide KSHV promoter association proﬁles with acetylated histone 3 at lysine 9 i
3, no dox treatment; fragments over 4-fold enriched are labeled. (B) Reactivation proﬁle, 12 h
Cy3 – Cy5 ratios of background-sub tracted IP-DNA over input DNA are shown with standardtranscript level initially doubles after reactivation (Nakamura et al.,
2003). All three of these viral proteins represent regulatory factors
with potential to alter the balance of viral and cellular factors in the
critical early stages of reactivation. Intriguingly, when K-bZIP was
deleted in the context of a recombinant BACmid clone, the expression
of several viral transcripts was enhanced during reactivation, although
reactivation overall was deﬁcient unless K-Rta was strongly over-
expressed (Kato-Noah et al., 2007). This ﬁnding supports a key role for
K-bZIP in modulating gene expression mediated by K-Rta, a function
which is critically important to reactivation under normal conditions
of infection.
K-bZIP was recruited preferentially to viral promoters on which it
has a repressive potential during reactivation of KSHV in naturally
infected PEL cells. The two modes of K-bZIP interaction with K-Rta
appear to be distinct in terms of their recruitment to individual
promoters over time. In the case of the repressive complex for the
ORF57 and K-bZIP promoters, the association is strong across the
time-course examined. Similarly, the K15 promoter shows signiﬁcant
occupancy by both K-Rta and K-bZIP as demonstrated in the by ChIP-
on-chip assay. In fact, all 3 repression targets of K-bZIP are among the
5 predominant sites of K-bZIP occupancy in TREx BCBL1-Rta cells
during reactivation. Because K-bZIP was previously demonstrated to
directly bind the PRDIII-I region of the IFN-beta promoter (Lefort et al.,
2007), we examined the ORF57, K15, and K-bZIP promoters for these
sites. Although limited sequence similarities exist in all three
promoters, closer matches were also found in non-associated
promoters such as K12, indicating that that IRF-3 response elements
cannot fully explain the binding speciﬁcity of K-bZIP in the context of
the viral genome. In contrast to the highly enriched repression sites,
the viral promoters with demonstrated synergistic potential involve a
lower level transient recruitment of K-bZIP in the context of
reactivation in PEL cells. One explanation for this relationship may
be through recruitment by K-bZIP of chromatin remodeling systems
such as SWI/SNF through hSNF5 interaction, or histone acetylase
activity via CBP; either of these mechanisms could lead to increased
accessibility of those promoters at later time points by a “hit-and-run”
mode of regulation. Alternatively, K-bZIP could mediate coactivation
of viral promoters indirectly by sequestering limiting factors impor-
tant for normal host gene transcription, freeing more core transcrip-
tion resources for direction by other speciﬁc viral transcription factors
such as K-Rta. Indeed, we see a broad repression of host gene
transcription in cells which overexpress K-bZIP (unpublished data),
and others have reported speciﬁc examples of this for CBP-mediated
transcription (Hwang et al., 2001). The argument for indirect synergy
is also intriguing when examining the cooperative reporter assay
results for the PAN and K7 promoters, which are overlapping and
collinear. Despite being entirely contained within the larger PAN
promoter fragment and sharing the same K-Rta response element, the
K7 promoter construct was synergistically activated by K-bZIP,
whereas the PAN promoter was not. If binding to a speciﬁc DNA
motif was the sole determinant of K-bZIP coactivation, we would
expect the same effect from K-bZIP cotransfection on both promoter
constructs. Interestingly, K-bZIP occupancy remains low or even
decreases on some promoters (K2, ORF9), despite a dramatic increase
in overall K-bZIP expression levels from 4 to 12 h. This suggests that
the distribution of K-bZIP across the viral genome is not static, but
rather governed by other cofactors or local conditions which shift over
the course of reactivation. It is conceivable that other early or delayed-
early genes may act on K-bZIP directly or through competition for
partners or sites by 12 h. Furthermore, by 24 h, the onset of late gene
expression and viral DNA replication may dramatically change thenTREx BCBL1-Rta cells. (A) Latent genome promoter associationwith acetylated histone
 af ter doxycycline treatment; promoter fragments above 8-fold are labeled. Normalized
 deviations determined by paired replicate spots.
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Fig. 7. Time-course analysis of factor recruitment to selected KSHV promoters during reactivation. All values are expressed as fold increase over IgG control pull-down, assayed by
real-time PCR at 4, 12, and 24 h after doxycycline treatment. ChIP was performed for IgG, K-Rta, K-bZIP, and H3acK9. (A) Five KSHV promoters were examined on which K-bZIP and
K-Rta synergize. (B) Proﬁles for two K-Rta target promoters repressed by K-bZIP expression. (C) Recruitment proﬁles for three additional K-Rta target promoters on which K-bZIP
had a little to no transcriptional effect. The ChIP elutions were assayed directly by real-time PCR after a 1:50 dilution. ORF9 and K-bZIP promoters are displayed in both linear and
log scale due to the strength of the H3acK9 association with these fragments.
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85T.J. Ellison et al. / Virology 387 (2009) 76–88environment in which viral genomes and K-bZIP interact. The limited
time course examined in this study was insufﬁcient to address these
questions, however the ﬁnding serves to illustrate the dynamic nature
of factor recruitment in a physiological context.
Examination of K-Rta recruitment across the entire complement of
viral promoters during reactivation also offers novel insight into
functions of this viral protein and its distribution across KSHV
promoters during reactivation. Although we observed signiﬁcant
occupancy at well-established target promoters (K-bZIP, PAN, ORF59,
etc), the most highly enriched promoters for K-Rta binding include
several onwhich it has only a moderate transactivation potential, such
as K2, K6, ORF37 (SOX), ORF75, K15, and the lytic origin region
(OriRNA). Because K-Rta has been demonstrated to act both through
direct DNA binding, as well as through host transcription factors such
as Oct-1, RBP-JK and K-RBP (Carroll et al., 2007; Chen et al., 2001;
Wang et al., 2001; West and Wood, 2003), this ﬁnding may reﬂect
differences in the mode of recruitment. ORF57 and K6 promoters
share a signiﬁcantly conserved motif for indirect K-Rta binding, which
includes overlapping RBP-JK and SP1 sites. The PAN and K12
promoters share another motif that lacks RBP-JK consensus and are
directly bound by puriﬁed K-Rta in vitro (Chang, Shedd, and Miller,
2005). Comparing K12 and PAN promoters, we found a much higher
occupancy of K-Rta on the K12 promoter across the same time points,
despite comparable levels of H3acK9 association, which would
otherwise suggest comparable promoter accessibility. This result is
in contrast to in vitro gel-shift studies, in which K-Rta was demon-
strated to have a higher afﬁnity for the PAN Rta-response element
than the K12 one, and further, that K-Rta binding to the K12 RRE was
enhanced by a 2-base mutation to more closely resemble the PAN
promoter (Song, Deng, and Sun, 2003). Our ﬁnding may therefore
reﬂect augmentation of K-Rta binding by host factors on the K12
promoter that do not similarly inﬂuence the PAN promoter. When this
manuscript was under review, another study examined the initial
transactivation targets of K-Rta using a fusion of the estrogen receptor
with ORF50 in combination with an inhibitor of translation (Bu et al.,
2008). Of the eight transcripts proposed as direct targets of K-Rta in
that work, seven showed appreciable promoter response to K-Rta in
our reporter assays (K2, K9, PAN, ORF37,ORF52, ORF57, and K14); only
ORF56 putative promoter failed to do so. The lack of luciferase activity
for the putative promoters of ORF56 may be explained by upstream
transcriptional initiation. Our ORF56 promoter fragment may be too
short to respond well to K-Rta, as it only includes 81 bp of sequence
upstream of the two reported transcriptional start sites mapped in
JSC-1 cells, due to initiation more than 350 bp upstream of the open
reading frame (Majerciak et al., 2006). As for ORF37, it has recently
been shown that this gene is transcribed from a site, 5′ of ORF35
(Haque et al., 2006), corresponding to our ORF35 putative promoter
which responded well to K-Rta activation in our reporter assay.
Intriguingly, our proximal ORF37 promoter fragment was strongly
activated by K-Rta in BCBL-1 reporter assays, but not in 293 cells,
raising the possibility that the transcriptional initiation of this region
may differ signiﬁcantly by cell line.
Investigations of KSHV chromatin associations are not without
precedent. However, this work represents the ﬁrst time such an
analysis has been performed across all putative promoter regions of
the viral genome. The genomic proﬁle obtained in latent PEL cells
for acetylated histone 3 at lysine 9 association agrees with previous
viral ChIP experiments using a limited set of primers to represent
key areas of the genome (Stedman et al., 2004). Both studies
demonstrated enrichment of the ORF73 promoter and terminal
repeat regions by H3acK9 immunoprecipitation. Our focus, however,
was on early and delayed-early regulation. During reactivation, we
observed broad and increasing H3acK9 association with most of the
viral promoters examined. One notable exception to this pattern
was the ORF57 promoter, which peaked at 12 h after induction and
subsequently decreased. Intriguingly, this decrease in H3acK9association corresponded to a decrease in K-bZIP and K-Rta
occupancy despite ample expression of the factors at that time
point as detected by immunoblotting. Given the known potential of
K-bZIP to repress K-Rta transactivation of the ORF57 promoter, this
behavior is suggestive of a role for chromatin remodeling in the
mechanism of repression, leading to a restriction of access to the
promoter. In contrast, ORF59, a delayed-early gene, was not substan-
tially increased in promoter association with H3acK9 until 24 h post
induction, at which point it coincided with strongly increased K-Rta
occupancy. This observation is also supportive of histone acetylation as
a potential temporal regulatory mechanism for the kinetics of K-Rta
transcriptional targets, althoughdifferent approachesmaybenecessary
to determine if modiﬁcation of viral chromatin actually controls the
distribution of K-Rta, or if changes in viral chromatin structure are
dictated by K-Rta recruitment. Similarly, the KSHV promoter proﬁle for
H3acK9 association during reactivation also has implications for
regulation of late gene expression. Our studies revealed two islands of
putative late genes (ORF19–28, and ORF61–65), which remained
relatively depleted for acetylated histone H3 during reactivation, in
sharp contrast to the signiﬁcant H3acK9 enrichment over much of the
rest of the viral genome. Given the potential of K-bZIP and K-Rta to
activatemany of these same late gene promoters, the lack of occupancy
for both factors during early and delayed early time points on these late
promoter islands further supports the notion that these regions are
regulated by a “closed” chromatin structure. This also raises the
possibility of a role for cellular factors such as CTCF in maintaining
boundaries between the early and late regions of the genome, as
reported for Epstein–Barr virus (Chau et al., 2006).
In summary, our ﬁndings advance the understanding of the roles of
K-bZIP and K-Rta in KSHV reactivation by revealing a novel capacity for
transcriptional synergy across a wide range of late gene promoters.
Additionally, this comprehensive analysis of KSHV transcription
demonstrates the speciﬁcity of the repressive role of K-bZIP on the
ORF57 and K-bZIP promoters. The identiﬁcation of K15 as an additional
potential target of this activity is also a novel ﬁnding, which better
informs our understanding of repression mediated by K-bZIP, and may
additionally suggest a role for K15 in the early lytic reactivation cascade.
The observation that K-bZIP is found most abundantly on viral
promoters that it represses underscores its evolving role as amodulator
of K-Rta activity, essential in orchestrating the complex sequence of
events after the lytic cycle is initiated. In addition, the K-Rta chromatin
and transactivation proﬁles represent the ﬁrst methodologically
unbiased comparison of K-Rta action and association across the entire
complementof putativeKSHVpromoters. Although theexamined setof
upstream regions cannot represent all possible regulatory regions of
the viral genome, our study represents an important initial survey of
the chromatin state and occupancy sites of these two critical KSHV
factors during lytic reactivation. The examination of changes in viral
factor and acetylated histone recruitment across the full set of
promoters in induced PEL cells sheds new light on the regulation of
reactivation, and offers signiﬁcant insight into the role of chromatin
structure in the control of KSHV replication.
Materials and methods
Cell culture
Human embryonic kidney epithelial 293 cells were grown in
monolayer cultures in Dulbecco's modiﬁed Eagle medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) or serum free
medium (Pro293a-CDM: Cambrex Bio Science, Walkersville, MD) in
the presence of 5% CO2. TREx BCBL1-Rta cells (Nakamura et al., 2003)
were maintained in RPMI 1640 supplemented with 15% fetal bovine
serum, 2 mM L-glutamine, and antibiotics, and induced for K-Rta
expression and subsequent KSHV reactivation by treatment with
100 ng/mL doxycycline for 4 h.
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The KSHV promoter library was created based on published work
where available, otherwise putative KSHV promoter regions of
approximately 500 bp upstream of AUG of respective open reading
frame were ampliﬁed by PCR using Pfu-turbo (Stratagene) with
corresponding primers. Ampliﬁed fragments were digested using
restriction enzyme sites (Fermentas), introduced via primer sequences
and inserted upstream of the ﬁreﬂy luciferase coding region (Luc) of
pGL3 basic vector (Promega). Either puriﬁed BCBL-1 genomic DNA or a
KSHV cosmid library (Izumiya et al., 2005) were used as the PCR
template. Cloned promoter sequences were conﬁrmed by sequencing,
and differences identiﬁed between cloned promoter sequence and
published KSHV genomic DNA sequence (Russo et al., 1996) were
summarized as a footnote in Table 1. These plasmids were then sent for
commercial ampliﬁcation and spotting onto glass slides (KamTek Inc.,
Gaithersburg, MD). The 83 individual viral promoter fragments were
spotted in duplicate to each of the array chips, along with 17 non-viral
control fragments. Hybridization speciﬁcity was conﬁrmed using
known KSHV promoters as probes.
Reporter assays
293 cells were seeded in 12-well plates at 1×105/well in 1.0 mL of
DMEM supplemented with 10% FBS and incubated at 37 °C with 5%
CO2. An equal amount of plasmid DNA, including the reporter and
control/expression plasmid, were transfected using the Fugene6
reagent by following the manufacturer's protocol (Roche). Cell lysates
were prepared with 1× Passive Lysis Buffer (Promega), 48 h after
transfection.
TREx BCBL1-Rta cells were seeded in 12-well plates at 5×106/well
in 1.0 mL of medium. Reporter plasmid (0.5 μg/well) was transfected
with Fugene6 HD by following the manufacturer's protocol (Roche).
Thirty-six hours after transfection, K-Rta expressionwas induced with
doxycycline, and cell lysates were prepared with 1× Passive Lysis
Buffer after 12 h induction of K-Rta. Luciferase assay was performedTable 1
Location of cloned KSHV promoters
Promoters Location Promoters Location Promoters Lo
K1 1–100 ORF22 36423–37111 ORF45 68
ORF4 642–1141 ORF23 40519–41105 ORF46 69
ORF6 2686–3209 ORF24 42791–43478 ORF47 69
ORF7 6146–6627 ORF25 42080–42776 ORF48 71
ORF8 8192–8698 ORF26 46401–46930 ORF49 72
ORF9 10777–11362 ORF27 47211–47865 ORF50 70
ORF10 13921–14520 ORF28 48318–48990 K–bZIP 74
ORF11 15171–15784 ORF29b 49855–50379 K8.1 75
K2 18554–19054 ORF30 49977–50622 ORF52 77
ORF02 19706–20203 ORF31 50258–50762 ORF53 77
K3 21835–22291 ORF32 50890–51402 ORF54 77
ORF70 1–100 ORF33 52228–52760 ORF55 79
K4 642–1141 ORF29a 54678–55320 ORF56 78
Ori-RNA 23613–24288 ORF34 54112–54673 ORF57 81
K5 26485–27134 ORF35 55144–55638 K9 85
K6 27425–28127 ORF36 55645–55975 K10.5 91
PAN 27426–28680 ORF37 56744–57272 K10 88
K7 27949–28620 ORF38 58145–58687 K11 93
ORF16 29461–30142 ORF39 60234–60766 ORF58 95
ORF17 32482–33105 ORF40 59800–60307 ORF59 96
ORF18 31806–32423 ORF41 61285–61826 ORF60 97
ORF19 34844–35482 ORF42 63308–63754 ORF61 10
ORF20 35573–36226 ORF43 64954–65527 ORF62 10
ORF21 34707–35379 ORF44 64307–64891 ORF63 10
Cloning of putative KSHV promoters. Putative KSHV promoters were cloned in pGL3 vector.
(Acc#U75698). Sequences were veriﬁed by sequencing analysis. Point mutations and delet
29787–29929), ORF19p (nt 35221 G to T), ORF20p (nt 35598 T to C), ORF23p (nt 40548 T to
50394 A to C), ORF32p (nt 51276 A to C), ORF47p (nt 70182 C to T), ORF60p (nt 98125 G toaccording to the manufacturer's protocol using a Lumat LB 9501
Luminometer (Wallac Inc., CA). At least two independent experiments
were performed in the same setting.
Western blotting
293 or TREx BCBL1-Rta cells were lysed in 1× RIPA buffer (10 mM
Tris–HCl [pH 7.5],1.0% NP-40, 0.1% sodiumdeoxycholate,150mMNaCl,
1 mM EDTA) supplemented with Complete™ protease inhibitor
cocktail (Roche) and frozen at −80 °C. Samples of these cell lysates
were balanced for total protein level using the Bio-Rad Protein Assay
reagent in comparison with a standard curve was generated using
bovine serum albumin (BSA, New England Biolabs), and 50 μg of total
cell lysateswere subjected to a SDS-polyacrylamide gel electrophoresis
(PAGE), and transferred to a polyvinylidene ﬂuoride (PVDF) mem-
brane (Millipore) using a semidry transfer apparatus (BioRad).
Following transfer, membraneswere incubated in 4% blocking solution
(1× TBST plus 4% dry milk power) for 30 min at room temperature.
Antibodies speciﬁc to K-Rta, K-bZIP, or GAPdH (Chemicon) were
applied to the membranes at 1:2000 dilution and incubated at room
temperature for 1 h with gentle rocking. Unbound antibody was
removed by 3 sequential washes with 1× TBST for 5 min each, after
which an HRP-conjugated goat anti-rabbit secondary antibody
(Amersham) was applied at 1:4000 dilution for 1 h at room
temperature with gentle rocking. After three additional washes with
1× TBST, the membrane was visualized using ECL Plus reagent (GE
Healthcare) and a digital image was captured using a FluorChem
biological imaging cabinet (Alpha Innotech).
Chromatin immunoprecipitation
TREx BCBL1-Rta cells (∼3×107/time point) were seeded in RPMI
plus 15% serum, at a density of 5×105/mL, allowed to recover for
∼15 h, then pulsed with 100 ng/mL doxycycline for 4 h, after which
time the media was changed to prevent overexpression of K-Rta. At
various time points following the treatment, the cultures werecation Promoters Location
577–69223 ORF64 103388–103995
405–69892 ORF65 112444–112906
916–70409 ORF66 113765–114279
382–71870 ORF67 114509–115052
539–73166 ORF68 114230–114767
899–71595 ORF69 115979–116668
691–74849 K12 118717–119351
409–75914 ORF72 123567–124218
198–77647 ORF73 Lc 127773–128309
666–78153 ORF73 Li 127496–127812
106–77666 K14 127238–127873
449–80058 ORF74 128817–129371
792–79435 ORF75 134442–135061
556–82089 K15 136281–137039
225–85875
397–91904 Controls and others
202–88879 Ori region 25062–25705
369–94017 Terminal repeat 801 bp NotI fragment
549–96029 ORF75–2 134890–135676
742–97248 ORF75–3 135643–136218
789–98304 Human Ch.19 162122–162594
0195–100733 Sumo–1 coding sequence
Ubc9 coding sequence
1195–101757 Yeast genomic DNA 4950–5393 (Acc#U18916)
0525–101207 Yeast genomic DNA 13798–14065 (Acc#U11581)
E. coli genomic DNA 3473366–3473971c (Acc#U00096)
Location of cloned promoters were listed, and number is based on published sequence
ion of direct repeat were observed following promoters, ORF16 promoter (deletion of
C), ORF24p (nt 43296 T to C), ORF30p (nt 50157 G to A and 50394 A to C), ORF31p (nt
A), ORF61p (nt 100324 G to A and 100241 C to T) and ORF69p (nt 116039 A to C).
Table 2
Primer sets for PCR ampliﬁcation for detection of KSHV promoters in ChIP assays
Forward primer Reverse primer Genomic pos. Size K-bZIP Class
ORF9p 5′-GAAACGGGGGAGTGACAGT-3′ 5′-GCGGACGGTAATTTGTGTCT-3′ 11222–11357 136 Synergy Early
K2pa 5′-CCCAAACCTTGTCAATTTGC-3′ 5′-GAACTCGCCAAAAAGTGAGC-3′ 18279–18425 147 Synergy Early
K6pa 5′-TTAAGCCAGGTTTCCATTGC-3′ 5′-TACAGAGACACGCCTCAAGC-3′ 27764–27886 123 Synergy Early
PANpa 5′-AAGGGTCAGCTTGAAGGATG-3′ 5′-GGCAGTCCCAGTGCTAAACT-3′ 28544–28678 135 No effect Early
ORF21p 5′-AATTACGCAGTCGGCAATTC-3′ 5′-CCGATCTATGGCGGTTTCTA-3′ 35154–35260 107 Synergy Late
KbZIPpa 5′-CAGTTTGGTGCAAAGTGGAG-3′ 5′-TCGACAACGGAGGAAATACC-3′ 74685–74814 130 Repression Early
ORF57pa 5′-TTCCATTAGGGTGAGCGAAG-3′ 5′-CCACTGGTACCACAAACGAA-3′ 81847–81953 107 Repression Early
ORF59p 5′-CACACTTCCACCTCCCCTAA-3′ 5′-CGCACAGAGAAATCACAGGA-3′ 96755–96849 95 No effect Del. early
ORF64p 5′-CGCTCAGGCTAACATTCCTC-3′ 5′-CAGTGGGACAAAACGGAGTT-3′ 103820–103958 139 Synergy Late
K12pa 5′-GTCGGTCTCCCCTCTTCTTT-3′ 5′-CTAGGTCCACGCTCACCTCT-3′ 118770–118891 122 No effect Late
Also listed are amplicon size (in bp), expression class (early, delayed early, late), and observed mode of K-bZIP/K-Rta interaction by reporter assay.
a Designates promoter fragment containing a published K-Rta response element.
87T.J. Ellison et al. / Virology 387 (2009) 76–88crosslinked and ﬁxed by addition of 1:10 volume formaldehyde
solution (0.1 M NaCl, 1 mM EDTA, 50 mM HEPES, pH 7.5, 11% HCHO
with CH3OH) for 10 min at room temperature. Fixed cells were
washed once in cold PBS, then in Buffer I (0.25% Triton X100, 10 mM
EDTA, 0.5 mM EGTA, 10 mM HEPES, pH 6.5), Buffer II (200 mM NaCl,
1 mM EDTA, 0.5 mM EGTA, 10 mM HEPES, pH 6.5), then pellets were
frozen at−80 °C until all samples were collected. The thawed pellets
were resuspended in with 0.8 mL ChIP lysis buffer (1% SDS, 10 mM
EDTA, 50 mM Tris–Cl, pH 8.1, plus Complete™ protease inhibitor
cocktail (Roche)), then disruptedwith two treatments on a Diagenode
Biorupter sonicator (15min, high intensity, 10 second on/off interval).
Sonicate was diluted 5× in dilution buffer plus inhibitors (1% Triton
X100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris–Cl, pH 8.1), then split
into tubes for immunoprecipitation. Chromatin complexes were
incubated with primary antibodies to K-Rta, K-bZIP (both puriﬁed
rabbit polyclonal), pre-immune rabbit serum, or an acetyl-speciﬁc
monoclonal antibody to histone 3, lysine 9 (Abcam) overnight at 4 °C,
then recovered with a 1:1 mix of TE-equilibrated protein A/protein G-
agarose beads, after addition of 5 μg sonicated salmon sperm DNA.
After 2 h at 4 °C, the beads were recovered and washed sequentially in
TSE buffer (0.1% SDS, 1% Triton X100, 2 mM EDTA, 20 mM Tris, pH 8.1)
plus 150 mM NaCl, TSE buffer plus 500 mM NaCl, Buffer III (0.25 M
LiCl, 1% NP-40, 1% Deoxycholate, 1 mM EDTA, 10 mM Tris, pH 8.1), and
twice with cold TE buffer. Each wash included 5 min rocking at 4 °C.
The bound DNA was then eluted in 10× bead volume (1% SDS, 0.1 M
NaHCO3) at room temperature for 10 min with agitation. Elutions
were incubated overnight at 65 °C to reverse crosslinks, diluted 3-fold
with 0.2 M NaCl, then DNA was precipitated with 2.5 volumes of
ethanol, washed with 70% ethanol, then puriﬁed on a Qiaquick PCR
cleanup column as per manufacturer's recommendations (Qiagen).
Viral promoter ChIP-on-chip
DNA enriched for association with K-Rta, K-bZIP, pre-immune
serum, or acetylated Histone 3, was concentrated in a Speedvac
(Savant) and subjected to one or two rounds of linear ampliﬁcation
as necessary using the Whole Genome Ampliﬁcation kit (Sigma) as
per manufacturer's recommendations, omitting the fragmentation
step (as the enriched DNA has already been fragmented by
sonication). These DNA fragment populations were labeled with
Cy3 or Cy5 using a 3DNA Array 900DNA Kit (Genisphere) as per
manufacturer's protocol, with omission of the digestion step, and a
16 h initial hybridization in formamide-containing buffer at 52 °C,
followed by a 4 h hybridization with the 3DNA Capture Reagent at
50 °C in an ozone-free tent. The slides were then scanned with an
Agilent DNA Microarray Scanner B at a 10 μm resolution. These
images were spotted and quantiﬁed using the Scanalyze software
(EisenSoftware), and normalized (0.5) calibrated ratios were aver-
aged to determine fold enrichment over the input DNA sample for
each pair of replicate spots.Real time qPCR for ChIP analysis
Eluted DNA from the ChIP assays were diluted 1:50 in ddH20 and
used as a template for qPCR using the primer sets listed in Table 2. 5 μL
of template were used per 25 μL reaction, all samples were analyzed in
triplicate using SYBR-green 2× master mix (Bio-Rad) on an iCycler iQ
thermal cycler (Bio-Rad). After an initial denaturation and activation
incubation of 3 min at 95 °C, 45 cycles of 3-step cycling were
performed with an annealing temperature of 60 °C. Melt curve
analysis was then performed to verify product speciﬁcity. Relative fold
induction over IgG for each immunoprecipitate and time-point were
determined by examining the change in threshold cycle number
(delta Ct), with standard deviation calibrated to account for variance
in both IgG and IP-DNA signal, then propagated logarithmically. All
primer sets were assayed for all time points of at least 2 independent
experimental repeats.
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